​

TherapeuticsMD (TXMD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TXMD Stock Rating

TherapeuticsMD stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (50.00%), 3 Hold (37.50%), 1 Sell (12.50%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 3 4 Strong Sell Sell Hold Buy Strong Buy

TXMD Price Target Upside V Benchmarks

TypeNameUpside
StockTherapeuticsMD-
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks21.96%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.08$2.08$2.08
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 24351--9
Oct, 24351--9
Sep, 24351--9
Aug, 24351--9
Jul, 24251--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 15, 2022Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$-30 $-23 $-16 $-9 $-2 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-25.83$-10.35$-0.55$-0.19$-0.05--
Avg Forecast$-20.17$3.01$-0.75$0.15$0.16$0.17$0.19
High Forecast$-20.17$3.01$-0.75$0.15$0.16$0.17$0.19
Low Forecast$-20.17$3.01$-0.75$0.15$0.16$0.17$0.19
Surprise %28.06%-443.85%-26.67%-226.67%-131.25%--

Revenue Forecast

$0 $20M $40M $60M $80M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$2.57M$69.96M$1.30M$1.76M---
Avg Forecast$97.28M$69.77M$2.00M$9.00M$9.20M$9.30M$9.50M
High Forecast$97.28M$69.77M$2.42M$9.00M$9.20M$9.30M$9.50M
Low Forecast$97.28M$69.77M$1.58M$9.00M$9.20M$9.30M$9.50M
Surprise %-97.36%0.27%-34.90%-80.43%---

Net Income Forecast

$-300M $-210M $-120M $-30M $60M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-172.41M$112.00M$-10.28M$-2.18M$-569.00K--
Avg Forecast$-190.53M$31.38M$-230.54M$1.57M$1.67M$1.77M$1.98M
High Forecast$-152.42M$31.38M$-184.43M$1.57M$1.67M$1.77M$1.98M
Low Forecast$-228.64M$31.38M$-276.65M$1.57M$1.67M$1.77M$1.98M
Surprise %-9.51%256.88%-95.54%-239.26%-134.06%--

TXMD Forecast FAQ

Is TherapeuticsMD stock a buy?

TherapeuticsMD stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that TherapeuticsMD is a favorable investment for most analysts.

What is TherapeuticsMD's price target?

TherapeuticsMD's price target, set by 8 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $2.08.

How does TherapeuticsMD stock forecast compare to its benchmarks?

TherapeuticsMD's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the specialty & generic drug manufacturers stocks industry (21.96%).

What is the breakdown of analyst ratings for TherapeuticsMD over the past three months?

  • November 2024: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • October 2024: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • September 2024: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is TherapeuticsMD’s EPS forecast?

TherapeuticsMD's average annual EPS forecast for its fiscal year ending in December 2026 is $0.17, marking a -440.00% decrease from the reported $-0.05 in 2025. Estimates for the following years are.

What is TherapeuticsMD’s revenue forecast?

TherapeuticsMD's average annual revenue forecast for its fiscal year ending in December 2026 is $9.3M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for.

What is TherapeuticsMD’s net income forecast?

TherapeuticsMD's net income forecast for the fiscal year ending in December 2026 stands at $1.77M, representing a -411.95% decrease from the reported $-569K in 2025. Projections indicate .